Gedeon Richter PLC (BUD:RICHTER)
Hungary · Delayed Price · Currency is HUF | Market Cap | 2.26T +15.2% |
| Revenue (ttm) | 925.14B +8.3% |
| Net Income | 229.48B -2.9% |
| EPS | 1,254.63 -2.8% |
| Shares Out | 182.39M |
| PE Ratio | 9.87 |
| Forward PE | 8.42 |
| Dividend | 508.00 (4.10%) |
| Ex-Dividend Date | Jun 3, 2026 |
| Volume | 156,902 |
| Average Volume | 218,850 |
| Open | 12,260 |
| Previous Close | 12,370 |
| Day's Range | 12,260 - 12,480 |
| 52-Week Range | 9,380 - 13,400 |
| Beta | 0.33 |
| RSI | 43.77 |
| Earnings Date | Apr 30, 2026 |
About Gedeon Richter
Gedeon Richter PLC researches, develops, manufactures, markets, and sells pharmaceutical products. It offers women’s healthcare products for contraceptives, endometriosis, fertility, menopause, vaginal infections, and uterine fibroids; and Femtech, a digital therapeutic solution to enhance women’s lives. It also provides central nervous system products, such as products for the treatment of chronic cerebral circulatory disorders and neuropathic pain; and anaesthetics, anti-anxiety medications, sleeping pills, and anti-epileptic medicines, as we... [Read more]
Financial Performance
In 2025, Gedeon Richter's revenue was 928.96 billion, an increase of 8.33% compared to the previous year's 857.55 billion. Earnings were 232.34 billion, a decrease of -2.89%.
Financial StatementsNews
Gedeon Richter Earnings Call Transcript: Q4 2025
2025 ended with strong revenue and profit growth, led by Women's Health and innovative products, despite FX losses and a challenging macro environment. Outlook for 2026 is high single-digit growth, with continued investment in R&D and new product launches.
Gedeon Richter Earnings Call Transcript: Q3 2025
Q3 2025 saw strong growth in innovative segments but was offset by headwinds in GenMed and CDMO, leading to a temporary revenue slowdown. Free cash flow hit a record high, and full-year Clean EBIT is projected to grow 8%-10%. Gross margin is expected to improve in Q4.
Gedeon Richter Earnings Call Transcript: Q2 2025
Pharma sales grew 10.7% YoY in H1 2025, with clean EBIT up 15% and Women's Health leading segment growth. FX volatility and inventory write-offs impacted cash flow, but guidance for 10% revenue and EBIT growth remains on track.
Gedeon Richter price target lowered to HUF 12,400 at RBC Capital
RBC Capital lowered the firm’s price target on Gedeon Richter (RGEDF) to HUF 12,400 from HUF 12,500 and keeps an Outperform rating on the shares.
Gedeon Richter Earnings Call Transcript: Q1 2025
Q1 2025 saw strong revenue and EBIT growth, driven by pharma sales and FX gains, with robust free cash flow and a solid cash position. Four biosimilar launches are planned within 12 months, and the outlook for general medicines and women's health remains positive.
Gedeon Richter upgraded to Buy from Hold at HSBC
HSBC analyst Raj Sinha upgraded Gedeon Richter (RGEDF) to Buy from Hold with a price target of HUF 11,700, up from HUF 11,000. The firm says the company’s long-term targets…
Gedeon Richter price target raised to HUF 12,390 from HUF 12,000 at Berenberg
Berenberg raised the firm’s price target on Gedeon Richter (RGEDF) to HUF 12,390 from HUF 12,000 and keeps a Buy rating on the shares.
Gedeon Richter Earnings Call Transcript: Q4 2024
Double-digit revenue and profit growth in 2024, with all business units contributing and strong free cash flow. 2025 guidance targets 10% growth despite lower milestone income, with cost controls and new product launches supporting outlook.
Gedeon Richter price target lowered to HUF 12,500 at RBC Capital
RBC Capital analyst Alistair Campbell lowered the firm’s price target on Gedeon Richter (RGEDF) to HUF 12,500 from HUF 12,900 and keeps an Outperform rating on the shares. Published first…
Gedeon Richter price target raised to HUF 12,500 from HUF 12,400 at RBC Capital
RBC Capital raised the firm’s price target on Gedeon Richter (RGEDF) to HUF 12,500 from HUF 12,400 and keeps an Outperform rating on the shares.
Gedeon Richter Earnings Call Transcript: Q3 2024
Revenue and net profit grew strongly year-over-year, driven by broad-based segment growth and successful M&A. Free cash flow and EBIT improved, with new product launches and biosimilar filings supporting future outlook. FX volatility and regulatory uncertainties remain key risks.
Gedeon Richter price target raised to HUF 12,000 from HUF 11,675 at Berenberg
Berenberg analyst Victoria Lambert raised the firm’s price target on Gedeon Richter to HUF 12,000 from HUF 11,675 and keeps a Buy rating on the shares.
Gedeon Richter Transcript: Investor Update
Women's healthcare is being transformed through strategic acquisitions, securing key assets like E4 and Donesta, and building in-house R&D. The business is on track to lead in Europe, with ambitious sales and margin targets, and a robust pipeline in contraception, fertility, and menopause.
Gedeon Richter price target raised to HUF 12,400 from HUF 12,200 at RBC Capital
RBC Capital raised the firm’s price target on Gedeon Richter to HUF 12,400 from HUF 12,200 and keeps an Outperform rating on the shares.
Gedeon Richter price target raised to HUF 12,200 from HUF 11,900 at RBC Capital
RBC Capital raised the firm’s price target on Gedeon Richter to HUF 12,200 from HUF 11,900 and keeps an Outperform rating on the shares.
Gedeon Richter price target raised to HUF 11,675 from HUF 10,310 at Berenberg
Berenberg raised the firm’s price target on Gedeon Richter to HUF 11,675 from HUF 10,310 and keeps a Buy rating on the shares.
Gedeon Richter Earnings Call Transcript: Q4 2023
Gedeon Richter price target lowered to HUF 12,000 at RBC Capital
RBC Capital lowered the firm’s price target on Gedeon Richter to HUF 12,000 from HUF 12,600 and keeps an Outperform rating on the shares.